Table 1.
Open in new tab

Clinical characteristics of patients in the COVID-19 vaccination cohort (n = 169)

Clinical parametersN (%)
Female88 (52.1)
Race
 Chinese122 (72.2)
 Malay17 (10.1)
 Indian14 (8.3)
 Others16 (9.4)
Age at first vaccination (years)a16.8 (14.7–19.5)
Disease duration at first vaccination (years)a5.0 (2.7–8.0)
Duration from second vaccination to sample collection (weeks)a4.7 (4.1–5.7)
Duration from second vaccination to M3 sample (months)a3.2 (3.0–3.7)
Duration from second vaccination to M6 sample (months)a6.0 (5.8–6.2)
Diagnosis
 JIA97 (57.5)
 SLE30 (17.7)
 JDM8 (4.7)
 Others34 (20.1)
Medications
 Prednisoloneb30 (17.8)
 MTX42 (24.9)
 AZA6 (3.6)
 MMF22 (13.0)
 SSZ40 (23.7)
 HCQ42 (24.9)
 Anti-tumour necrosis factor57 (33.7)
 Tocilizumab5 (3.0)
Holding MTX after vaccination for 1 week, n = 4230 (88.1)
Holding MMF after vaccination for 1 week, n = 2213 (59.1)
Clinical parametersN (%)
Female88 (52.1)
Race
 Chinese122 (72.2)
 Malay17 (10.1)
 Indian14 (8.3)
 Others16 (9.4)
Age at first vaccination (years)a16.8 (14.7–19.5)
Disease duration at first vaccination (years)a5.0 (2.7–8.0)
Duration from second vaccination to sample collection (weeks)a4.7 (4.1–5.7)
Duration from second vaccination to M3 sample (months)a3.2 (3.0–3.7)
Duration from second vaccination to M6 sample (months)a6.0 (5.8–6.2)
Diagnosis
 JIA97 (57.5)
 SLE30 (17.7)
 JDM8 (4.7)
 Others34 (20.1)
Medications
 Prednisoloneb30 (17.8)
 MTX42 (24.9)
 AZA6 (3.6)
 MMF22 (13.0)
 SSZ40 (23.7)
 HCQ42 (24.9)
 Anti-tumour necrosis factor57 (33.7)
 Tocilizumab5 (3.0)
Holding MTX after vaccination for 1 week, n = 4230 (88.1)
Holding MMF after vaccination for 1 week, n = 2213 (59.1)
a

Data are presented as median (interquartile range).

b

Median dose of prednisolone = 5 mg/day (range 3–15 mg/day). COVID-19: coronavirus disease 2019.

Table 1.
Open in new tab

Clinical characteristics of patients in the COVID-19 vaccination cohort (n = 169)

Clinical parametersN (%)
Female88 (52.1)
Race
 Chinese122 (72.2)
 Malay17 (10.1)
 Indian14 (8.3)
 Others16 (9.4)
Age at first vaccination (years)a16.8 (14.7–19.5)
Disease duration at first vaccination (years)a5.0 (2.7–8.0)
Duration from second vaccination to sample collection (weeks)a4.7 (4.1–5.7)
Duration from second vaccination to M3 sample (months)a3.2 (3.0–3.7)
Duration from second vaccination to M6 sample (months)a6.0 (5.8–6.2)
Diagnosis
 JIA97 (57.5)
 SLE30 (17.7)
 JDM8 (4.7)
 Others34 (20.1)
Medications
 Prednisoloneb30 (17.8)
 MTX42 (24.9)
 AZA6 (3.6)
 MMF22 (13.0)
 SSZ40 (23.7)
 HCQ42 (24.9)
 Anti-tumour necrosis factor57 (33.7)
 Tocilizumab5 (3.0)
Holding MTX after vaccination for 1 week, n = 4230 (88.1)
Holding MMF after vaccination for 1 week, n = 2213 (59.1)
Clinical parametersN (%)
Female88 (52.1)
Race
 Chinese122 (72.2)
 Malay17 (10.1)
 Indian14 (8.3)
 Others16 (9.4)
Age at first vaccination (years)a16.8 (14.7–19.5)
Disease duration at first vaccination (years)a5.0 (2.7–8.0)
Duration from second vaccination to sample collection (weeks)a4.7 (4.1–5.7)
Duration from second vaccination to M3 sample (months)a3.2 (3.0–3.7)
Duration from second vaccination to M6 sample (months)a6.0 (5.8–6.2)
Diagnosis
 JIA97 (57.5)
 SLE30 (17.7)
 JDM8 (4.7)
 Others34 (20.1)
Medications
 Prednisoloneb30 (17.8)
 MTX42 (24.9)
 AZA6 (3.6)
 MMF22 (13.0)
 SSZ40 (23.7)
 HCQ42 (24.9)
 Anti-tumour necrosis factor57 (33.7)
 Tocilizumab5 (3.0)
Holding MTX after vaccination for 1 week, n = 4230 (88.1)
Holding MMF after vaccination for 1 week, n = 2213 (59.1)
a

Data are presented as median (interquartile range).

b

Median dose of prednisolone = 5 mg/day (range 3–15 mg/day). COVID-19: coronavirus disease 2019.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close